Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIP's Role in the Glucose-Lowering Effect of Sitagliptin
NCT03845179Completed
- Sponsor
- Gentofte Hospital
- Start
- May 2019
- Primary completion
- Feb 2020
- Countries
- 1
01
Overview
Randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Placebo Arm with Sitagliptin Arm (2 arms). Primary endpoint: C-peptide at 5 hours. Started May 2019; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03845179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03845179.